Effect of High Dose U-500 Regular Insulin in Severely Insulin Resistant Type 2 Diabetics

What is the Study about?

The purpose of this study is to learn more about how U-500 regular insulin can be effectively used to treat type 2 diabetes. Most insulin treated patients with type 2 diabetes take U-100 insulin, but if they require large doses (such as >150 units a day), they may experience pain at the site of injection and the absorption of the insulin is unpredictable, leading to poor glucose control. 

To overcome these problems, doctors sometimes switch to a more concentrated form of insulin called U-500 insulin. U-500 is five times as concentrated as U-100 insulin and therefore delivers an equivalent dose of insulin in much lesser volume. 

How to best use U-500 insulin is not certain. The investigators are not really sure how long a given dose is effective in patients who require large doses (>150 units of U-100 insulin), so are not sure of how often the drug should be administered. 

In this study, the investigators will determine how effective two different doses of U-500 regular insulin (100 U and 200 U) are in lowering blood sugar and how long these two doses last. This information will help doctors develop better treatment plans for patients with severe insulin resistant type 2 diabetes.

Eligibility to participate

You may be eligible to participate in this Study if you:

  • Have type 2 diabetes
  • Are between the age of 30-65
  • Are on more than 200 units of insulin per day, if only using insulin to treat your diabetes
  • Or are on 150 units of insulin along with other non-insulin diabetes medication

This study does not accept healthy participants.
This study is currently recruiting participants.

What is involved in the Study?

  • Safety stopping using non-insulin diabetes medication 1 week prior to study visit
  • Spending 1 day and 2 nights at the University of Minnesota Masonic Clinical Research Unit (MCRU)
  • Taking a dose of U-500 regular insulin during stay at MCRU
  • Completing the procedure a second time 2 to 4 weeks later

Principal Investigator

Elizabeth Seaquist, MD

For More Information

Anjali Kumar, PA-C
(612) 624-0470